Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 13/20 | 0.61 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.50 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.47 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.44 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.44 |
| ▸ | FAAH | O00519 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1712903 | 1.00 | NOD1 (0.61) | NOD1SLC6A5HAO1PLA2G2APLA2G5 | |
| SCHEMBL5162312 | 1.00 | NOD1 (0.61) | NOD1SLC6A5HAO1PLA2G2APLA2G5 | |
| SCHEMBL1449056 | 0.98 | NOD1 (0.59) | NOD1SLC6A5HAO1PLA2G2APLA2G5 | |
| SCHEMBL1449055 | 0.98 | NOD1 (0.59) | NOD1SLC6A5HAO1PLA2G2APLA2G5 | |
| Lactic Acid SCHEMBL28953041 | 0.94 | NOD1 (0.56) | NOD1SLC6A5HAO1PLA2G2APLA2G5 | |
| SCHEMBL22996019 | 0.89 | NOD1 (0.77) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL5122358 | 0.89 | NOD1 (0.77) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL17941648 | 0.89 | NOD1 (0.77) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL9829330 | 0.89 | NOD1 (0.77) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL131586 | 0.89 | NOD1 (0.77) | NOD1SLC6A5FAAHMEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730197-B1 | METHODS FOR INDUCING AUTOLYSIS IN INFECTIOUS BACTERIA | HAPTOGEN LTD (GB) | 2012-03-07 | — | — | EP | claimed |
| EP-0994961-A4 | HOMOSERINE LACTONES BIOFILM REGULATING COMPOUNDS AND THEIR METHODS OF USE | UNIV MONTANA RES DEV INST (US) | 2003-01-15 | — | — | EP | claimed |
| EP-0994961-A2 | HOMOSERINE LACTONES BIOFILM REGULATING COMPOUNDS AND THEIR METHODS OF USE | The Research and development Institute, Inc (US) | 2000-04-26 | — | — | EP | claimed |
| WO-1998058075-A2 | HOMOSERINE LACTONES BIOFILM REGULATING COMPOUNDS AND THEIR METHODS OF USE | THE RESEARCH AND DEVELOPMENT INSTITUTE, INC. (US) | 1998-12-23 | — | — | WO | claimed |
| CN-115362182-A | Hydrophilic oil-repellent polymers | 住友化学株式会社 | 2022-11-18 | — | — | CN | disclosed |
| CN-107308186-A | It is used for the biomedical applications and the bismuth mercaptan of other purposes for the treatment of for including bacterial biof iotalm as antiseptic | 微生物公司 | 2017-11-03 | — | — | CN | disclosed |
| US-20170043020-A1 | ANTIBODY-MEDIATED DISRUPTION OF QUORUM SENSING IN BACTERIA | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-02-16 | — | — | US | disclosed |
| EP-2842565-B1 | Antibody-mediated disruption of quorum sensing in bacteria | SCRIPPS RESEARCH INST (US) | 2016-08-24 | — | — | EP | disclosed |
| US-9394371-B2 | Antibody-mediated disruption of quorum sensing in bacteria | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-07-19 | — | — | US | disclosed |
| US-20160194683-A1 | Gas Biosensors | WILLIAM MARSH RICE UNIVERSITY | 2016-07-07 | — | — | US | disclosed |
| EP-2994537-A2 | COMPOSITIONS, SYSTEMS AND METHODS FOR PROTECTING GENETICALLY MODIFIED ORGANISMS FROM UNAUTHORIZED USE OR RELEASE INTO THE ENVIRONMENT | Microbial Robotics, LLC (US) | 2016-03-16 | — | — | EP | disclosed |
| US-20150140585-A1 | GAS BIOSENSORS | WILLIAM MARSH RICE UNIVERSITY | 2015-05-21 | — | — | US | disclosed |
| EP-0994961-A4 | HOMOSERINE LACTONES BIOFILM REGULATING COMPOUNDS AND THEIR METHODS OF USE | UNIV MONTANA RES DEV INST (US) | 2003-01-15 | — | — | EP | disclosed |
| WO-2002102370-A1 | BIOFILM DEGRADING OR SLOUGHING COMPOSITIONS AND METHODS | UNISEARCH LIMITED (AU) | 2002-12-27 | — | — | WO | disclosed |
| US-6423312-B1 | TREATING CYSTIC FIBROSIS WITH CONNECTIVE TISSUE ACTIVATING PEPTIDE III, HEPARINASES, HYALURONIDASES AND CHONDROITINASES | INSIGHT STRATEGY & MARKETING LTD. (IL) | 2002-07-23 | — | — | US | disclosed |
| CN-1354795-A | Polypeptides having lactonohydrolase activity and nucleic acids encoding same | NOVOZYMES BIOTECH INC (US) | 2002-06-19 | — | — | CN | disclosed |
| US-20020064858-A1 | COMPOSITIONS INCLUDING GLYCOSAMINOGLYCANS DEGRADING ENZYMES AND USE OF SAME AGAINST SURFACE PROTECTED BACTERIA | INSIGHT BIOPHARMACEUTICALS LTD. (IL) | 2002-05-30 | — | — | US | disclosed |
| US-6395282-B1 | CARRIER MOLECULE CONJUGATED TO SPECIFIC AUTOINDUCERS; VACCINES FOR THE TREATMENT AND PREVENTION OF INFECTION | UNIVERSITY OF ROCHESTER | 2002-05-28 | — | — | US | disclosed |
| EP-0994961-A2 | HOMOSERINE LACTONES BIOFILM REGULATING COMPOUNDS AND THEIR METHODS OF USE | The Research and development Institute, Inc (US) | 2000-04-26 | — | — | EP | disclosed |
| WO-1998058075-A2 | HOMOSERINE LACTONES BIOFILM REGULATING COMPOUNDS AND THEIR METHODS OF USE | THE RESEARCH AND DEVELOPMENT INSTITUTE, INC. (US) | 1998-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170043020-A1 | ANTIBODY-MEDIATED DISRUPTION OF QUORUM SENSING IN BACTERIA | CD47, TLR5, ANTXR2 | NOD1 52/4885SLC6A5 2228/4885HAO1 3707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.